Walsh D M, Stratton S C, Harvey F J, Beresford I J, Hagan R M
Department of Pharmacology, Glaxo Research & Development Ltd, Stevenage, UK.
Psychopharmacology (Berl). 1995 Sep;121(2):186-91. doi: 10.1007/BF02245629.
The non-peptide NK2 receptor antagonist, GR159897, was evaluated in two putative models of anxiety, the mouse light-dark box and the marmoset human intruder response test. Effects were compared to the structurally dissimilar NK2 antagonist, (+/-) SR48968 and the benzodiazepines, diazepam and chlordiazepoxide. GR159897 (0.0005-50 micrograms/kg SC) caused significant and dose-dependent increases in the amount of time mice spent in the more aversive light compartment of the light-dark box, with no effect on locomotor activity. (+/-)SR48968 (0.0005-0.5 microgram/kg SC) and diazepam (1-1.75 mg/kg SC), also increased time spent in the light compartment, without effect on locomotor activity. In the marmoset human intruder response test, GR159897 (0.2-50 micrograms/kg SC) significantly increased the amount of time marmosets spent at the front of the cage during confrontation with a human observer ("threat"). Similar effects were produced by (+/-)SR48968 (10-50 micrograms/kg SC) and chlordiazepoxide (0.3-3.0 mg/kg SC). These results provide further evidence, in both rodent and primate species, for the ability of NK2 antagonists to restore behaviours which have been suppressed by novel aversive environments. Such effects indicate that NK2 antagonists may have anxiolytic activity.
非肽类NK2受体拮抗剂GR159897在两种假定的焦虑模型(小鼠明暗箱试验和狨猴人类入侵者反应试验)中进行了评估。将其效果与结构不同的NK2拮抗剂(±)SR48968以及苯二氮䓬类药物地西泮和氯氮䓬进行了比较。GR159897(0.0005 - 50微克/千克,皮下注射)使小鼠在明暗箱中较厌恶的亮区停留的时间显著增加,且呈剂量依赖性,对运动活性无影响。(±)SR48968(0.0005 - 0.5微克/千克,皮下注射)和地西泮(1 - 1.75毫克/千克,皮下注射)也增加了在亮区停留的时间,对运动活性无影响。在狨猴人类入侵者反应试验中,GR159897(0.2 - 50微克/千克,皮下注射)显著增加了狨猴在与人类观察者对峙(“威胁”)期间在笼子前部停留的时间。(±)SR48968(10 - 50微克/千克,皮下注射)和氯氮䓬(0.3 - 3.0毫克/千克,皮下注射)产生了类似的效果。这些结果在啮齿动物和灵长类动物中都进一步证明了NK2拮抗剂能够恢复被新的厌恶环境所抑制的行为。这种效果表明NK2拮抗剂可能具有抗焦虑活性。